|
Daily Medical Update
Depression & Anxiety in Primary Care (SSRIs/SNRIs)
Sunday, February 15, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
1. SSRIs/SNRIs reduce pediatric anxiety symptoms but carry a measurable suicidal ideation signal
J Child Adolesc Psychopharmacol (2026) - Systematic Review/Meta-Analysis
Key Findings
- Across 15 RCTs (n=2,083), SSRI/SNRI treatment reduced anxiety symptoms versus placebo (SMD -0.49, 95% CI -0.65 to -0.33).
- The same evidence base showed higher suicidal ideation risk versus placebo (RR 3.51, 95% CI 1.51-8.16), supporting closer early follow-up after initiation.
📋 Practice Implication: For adolescents/young adults started on SSRIs/SNRIs, schedule early safety check-ins and explicit family warning-sign counseling.
|
2. Venlafaxine ER improved generalized anxiety outcomes versus placebo in adults
Int Clin Psychopharmacol (2025) - Randomized Controlled Trial
Key Findings
- In an 8-week double-blind trial (n=357), venlafaxine ER achieved greater HAM-A improvement than placebo (P=0.012).
- Functional and global-improvement secondary outcomes also favored venlafaxine ER versus placebo across clinician- and patient-rated scales.
📋 Practice Implication: Use venlafaxine ER as a high-value SNRI alternative when first SSRI strategy is insufficient or poorly tolerated.
|
3. Adjunctive cariprazine produced additional symptom gains in antidepressant-treated MDD
J Affect Disord (2026) - Bayesian Mega-analysis of Two Randomized Trials
Key Findings
- Mega-analysis of 1,501 participants found adjunctive cariprazine improved depressive symptoms versus placebo at 1.5 mg/day (β=-0.319, P<0.001) and 3 mg/day (β=-0.233, P=0.002).
- Early week-2 improvement predicted continued week-6 benefit, whereas weak early response signaled lower probability of later gain without treatment adjustment.
📋 Practice Implication: Apply measurement-based care at 2-4 weeks to identify partial responders early and consider evidence-based augmentation sooner.
|
4. Sexual adverse-effect risk varies meaningfully across antidepressants
Neurosci Biobehav Rev (2025) - Systematic Review/Network Meta-analysis
Key Findings
- Network meta-analysis of 30 RCTs (n=18,157) found large between-drug differences in ejaculation dysfunction risk, with highest-risk agents showing markedly higher odds versus comparators.
- Higher sexual adverse-effect burden was associated with greater withdrawal pressure in multiple comparisons, threatening persistence and remission.
📋 Practice Implication: Include sexual side-effect risk in first-line drug selection and normalize early side-effect discussions to prevent avoidable discontinuation.
|
5. Insomnia risk increases modestly with newer antidepressants in youth MDD trials
J Am Acad Child Adolesc Psychiatry (2025) - Systematic Review/Meta-Analysis
Key Findings
- Across pediatric MDD RCTs, newer-generation antidepressants showed higher odds of insomnia adverse events than placebo during acute treatment windows.
- Parallel pediatric anxiety/OCD trial analyses showed higher insomnia-event rates versus placebo in the same direction, supporting early sleep-focused monitoring after SSRI/SNRI start.
📋 Practice Implication: At initiation, pre-empt sleep adverse effects with dosing-time adjustments, sleep-hygiene counseling, and rapid follow-up if insomnia worsens.
|
|
Recent high-yield evidence reinforces SSRIs/SNRIs as effective first-line pharmacotherapy for anxiety/depression while highlighting two practice-critical safeguards: early suicidality monitoring (especially in youth) and proactive adverse-effect management (sleep and sexual function). For partial responders, measurement-based early reassessment supports faster optimization, including rational augmentation.
|
|